Depakote
Product Images NDC 54868-4959

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Depakote (NDC 54868-4959). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Depakote® Er Divalproex Sodium Extended-release Tablets 500 mg Package Label (4959)

Depakote ER 500 mg extended release tablets label from Physicians Total Care, Inc. The label indicates 60 tablets per container and includes active ingredient divalproex sodium. It features dosing information, storage instructions, and regulatory warnings, including federal prescription restrictions.*

FDA Label Image

Depakote® Er Divalproex Sodium Extended-release Tablets 250 mg Package Label (5525)

Depakote ER 250 MG extended release tablets label by Physicians Total Care, Inc. The label indicates 30 tablets per container. It includes cautionary text about federal dispensing laws, storage instructions, and a barcode. The active ingredient is divalproex sodium.*

FDA Label Image

Chemical Structure Of Divalproex Sodium (Depakote Er 01)

Chemical structure diagram of the active ingredient in Depakote, depicting atoms and bonds including sodium (Na) ions and organic groups with ethyl side chains.*

FDA Label Image

Figure 3 (Depakote Er 02)

A bar graph comparing two groups labeled Placebo and Depakote ER. The Depakote ER group shows a higher value at 1.2 compared to the Placebo group at 0.6. An asterisk indicates a statistically significant difference with p=0.006.*

FDA Label Image

Figure 1 (Depakote Er 03)

A line graph comparing the percentage reduction in CPS rate between Depakote and placebo across patients. The y-axis shows percent reduction in CPS rate, ranging from -100% (worsening) to 100% (improvement), with a baseline at zero indicating no change. The x-axis represents the percentage of patients from 100% to 0%. Depakote shows a higher rate of improvement compared to placebo.*

FDA Label Image

Figure 2 (Depakote Er 04)

A line graph comparing the percentage reduction in CPS rate between high dose and low dose Depakote among patients. The x-axis represents the percentage of patients from 100 to 0, and the y-axis shows the percentage reduction in CPS rate from -100% to 100%. Improvement and worsening are indicated on the y-axis. Two curves represent high dose Depakote (solid line) and low dose Depakote (dashed line).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.